Could a simple Self-Swab revolutionize cervical cancer screening?

NCT ID NCT07768787

First seen Aug 17, 2026 ยท Last updated Aug 17, 2026

Summary

This trial tests whether a vaginal self-sampling device can accurately detect high-risk human papillomavirus (HPV) compared to samples collected by a clinician. About 1,000 women aged 30-64, either regular screening attendees or those who haven't been screened in 3+ years, will provide both self-collected and clinician-collected samples. The goal is to see if self-sampling could be a reliable option to increase participation in cervical cancer screening programs.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Abbott Multi-Collect Specimen Collection Swab (a vaginal self-sampling device)
What this could lead to
If self-sampling proves accurate, it could make cervical cancer screening easier and more accessible, potentially increasing participation and early detection.
What could go wrong
The trial is a validation study, so it may show that self-collected samples are less accurate than clinician-collected ones. Also, results may not apply to all populations or screening settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • O+ Medicale

    Brussels, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.